David A.  Williams

David A. Williams, MD

President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Associate Chair, Pediatric Oncology, Dana-Farber Cancer Institute; Chief, Division of Hematology/Oncology, Boston Children's Hospital; Director of Clinical and Translational Research, Boston Children's Hospital

Leland Fikes Professor of Pediatrics, Harvard Medical School

  • Contact: 617-355-8246

  • Fax: 617-730-0641

Medical Services


  • Fanconi Anemia and Other Genetic Disorders
  • Viral Vectors
  • Blood Formation
  • Hematopoiesis
  • Gene Therapy
  • Aplastic Anemia
  • Chronic Granulomatous Disease


  • Hematology / Oncology
  • Medicine


  • English


  • Bone Marrow Failure Program
  • Myelodysplastic Syndrome Specialty Program
  • Hematology / Oncology
To schedule an appointment: Call 617-355-8246 or Request an Appointment

Experience and Education



Indiana University School of Medicine, 1979

Indianapolis, IN


Cincinnati's Children's Hospital Medical Center, 1980

Cincinnati, OH


Cincinnati's Children's Hospital Medical Center, 1982

Cincinnati, OH


Boston Children's Hospital/Dana-Farber Cancer Institute, 1985

Boston, MA


  • Pediatrics


Dr. Williams major research interests are in the study of blood stem cell biology, blood formation, leukemia and the treatment of genetic blood diseases using gene therapy. He has published over 250 peer-reviewed manuscripts and textbook chapters. He was an investigator of the HHMI for 16 years. He has been continuously funded by the NIH since 1986. His laboratory co-discovered and cloned Interleukin-11 (Neumega TM) and carried out developmental studies that assisted in obtaining FDA approval of this drug. His laboratory also described and patented the use of fibronectin in retrovirus-mediated gene transfer, now nearly universally used (as Retronectin TM) in clinical gene therapy trials and basic research utilizing gene transfer. His most recent focus has been on exploring the role of Rho GTPases in hematopoietic stem cell biology. He and Dr. Yi Zheng have developed a new small molecule inhibitor of Rac GTPases that is being investigated collaboratively in cancer therapies. Thus, work in the Williams laboratory has led to multiple patents and product licenses for new therapies in human diseases. He also leads several gene therapy trials in immunodeficiency and neurologic disease.

Professional History

To schedule an appointment: Call 617-355-8246 or Request an Appointment


View Location:

The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944